Imunon, Inc. (LON:0HUZ)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 8.52M -20.0% |
| Revenue (ttm) | n/a |
| Net Income | -10.66M |
| EPS | -7.10 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 540 |
| Average Volume | 225 |
| Open | 0.9900 |
| Previous Close | 0.9307 |
| Day's Range | 0.8801 - 0.9900 |
| 52-Week Range | 0.8801 - 47.4000 |
| Beta | 2.09 |
| RSI | 48.52 |
| Earnings Date | Mar 27, 2026 |
About Imunon
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company’s lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such... [Read more]
News
IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY
Strategic Restructuring Eliminates Expenses Not Essential to the Phase 3 Study Khursheed Anwer, Ph.D., Executive Vice President and Chief Scientific Officer, will retire after nearly 12 years at the c...
IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules
LAWRENCEVILLE, N.J., Dec. 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has ent...
IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026
Enrollment in the Pivotal Phase 3 OVATION 3 Study Advances Company Toward Future BLA Filing New Data from MRD Study Reinforces IMNN-001's Promise as a Potential Breakthrough Immunotherapy LAWRENCEVILL...
Imunon, Inc. (IMNN) Discusses IMNN-001 Immunotherapy Progress and Milestones in OVATION 3 Ovarian Cancer Study - Slideshow
2025-11-21. The following slide deck was published by Imunon, Inc.
Imunon Inc (IMNN) Q3 2025 Earnings Call Highlights: Promising Advances in Immunotherapy and ...
Imunon Inc (IMNN) Q3 2025 Earnings Call Highlights: Promising Advances in Immunotherapy and Strategic Financial Management
Imunon, Inc. (IMNN) Q3 2025 Earnings Call Transcript
Imunon, Inc. ( IMNN) Q3 2025 Earnings Call November 13, 2025 11:00 AM EST Company Participants Stacy Lindborg - President, CEO & Director Douglas V. Faller - Chief Medical Officer Kimberly Graper - C...
Q3 2025 Imunon Inc Earnings Call Transcript
Q3 2025 Imunon Inc Earnings Call Transcript
Imunon (IMNN) Q3 2025 Earnings Call Transcript
Imunon (IMNN) Q3 2025 Earnings Call Transcript
Imunon GAAP EPS of -$1.16 beats by $0.65
IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update
R&D Day showcased remarkable Investigator optimism, continued strengthening supportive data, and significant progress with Phase 3 OVATION 3 Study in pursuit of first frontline immunotherapy for advan...
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE: EPC) is projected to report quarterly earnings at $0.81 per share on revenue of $534.10 million. • National Energy Services (NASDAQ...
Exploring Imunon's Earnings Expectations
Imunon (NASDAQ: IMNN) is set to give its latest quarterly earnings report on Thursday, 2025-11-13. Here's what investors need to know before the announcement. Analysts estimate that Imunon will repor...
Imunon Q3 2025 Earnings Preview
IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer
Webcast Recording and Symposium Slides Now Available LAWRENCEVILLE, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-m...
IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer
Event being held today at 8:00 a.m. ET in New York City features presentations from Ovarian Cancer Key Opinion Leaders, Clinicians, Statistical Experts, and IMUNON executives Investors, stakeholders, ...
IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment
Investors and stakeholders invited to attend in person in New York City or via live webcast on Monday, November 10th at 8:00 a.m. ET
IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025
LAWRENCEVILLE, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Compa...
IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer
Investor event in New York City to provide update on pivotal Phase 3 study of IMNN-001; offering in-person or virtual attendance on November 10, 2025
IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting
Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congress 2025 LAWRENCEVILLE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- IMUNON , In...
IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting
IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per plan LAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company in Ph...
IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer
Investor event to provide update on pivotal Phase 3 study of IMNN-001 to be held in New York City on November 10, 2025 Program will feature presentations from ovarian cancer thought leaders, Phase 3 s...
IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences
Company seeks strategic partners to advance novel PlaCCine technology LAWRENCEVILLE, N.J., Oct. 17, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company focused on developin...
IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress
Prestigious European Society for Medical Oncology Conference “trials-in-progress” session Pivotal OVATION 3 trial of its DNA-mediated immunotherapy in newly diagnosed patients underway Company on trac...
Imunon (IMNN) Shares New Positive Data from Phase 2 OVATION 2 Study
Imunon (IMNN) Shares New Positive Data from Phase 2 OVATION 2 Study